HALO earnings

Announcing New $1 billion Share Repurchase ProgramProjecting to Buy Back at Least $400 million in 2026Total Revenue Increased 42% YOY to $377 millionRoyalty Revenue Increased 43% YOY to $241 millionReiterating 2026 Financial Guidance Ranges:Total Revenue of $1.710 - $1.810 billion, YOY Growth of 22% - 30%Royalty Revenue of $1.130 - $1.170 billion, YOY Growth of 30% - 35%Adjusted EBITDA of $1.125 - $1.205 billion, YOY Growth of 71% - 83%1Non-GAAP Diluted EPS of $7.75 - $8.25, YOY Growth of 87% - 99%1SAN DIEGO, May 11, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today reported its financial and operating results for the first quarter ended March

SAN DIEGO, April 30, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced it will release its first quarter 2026 financial and operating results on Monday, May 11, 2026, following the close of trading.Halozyme will host a conference call on Monday, May 11, 2026 at 1:30pm PT/4:30pm ET to discuss the results. The conference call may be accessed live with pre-registration via this link: https://events.q4inc.com/analyst/178516398?pwd=q41k1S5tA live webcast and replay of the conference call will also be available through the "Investors" section of Halozyme's corporate website at www.halozyme.com.About HalozymeHalozyme is a biopharmaceutical company advancing

Full Year 2025 Total Revenue Increased 38% YOY to Record $1.397 billionFull Year 2025 Royalty Revenue Increased 52% YOY to Record $868 millionCompleted Acquisitions of Elektrofi's Hypercon™ Technology and Surf Bio's Hyperconcentration TechnologyReiterating 2026 Financial Guidance Ranges:Total Revenue of $1.710 - $1.810 billion, YOY Growth of 22% - 30%Adjusted EBITDA of $1.125 - $1.205 billion, YOY Growth of 71% - 83%1Non-GAAP Diluted EPS of $7.75 - $8.25, YOY Growth of 87% - 99%1SAN DIEGO, Feb. 17, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today reported its financial and operating results for the full year and fourth quarter ended December 

SAN DIEGO, Feb. 10, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced it will release its fourth quarter and full year 2025 financial and operating results on Tuesday, February 17, 2026, following the close of trading. Halozyme will host a conference call on Tuesday, February 17, 2026 at 1:30pm PT/4:30pm ET to discuss the results. The conference call may be accessed live with pre-registration via this link: https://events.q4inc.com/analyst/624893800?pwd=q3lpEa6F A live webcast and replay of the conference call will also be available through the "Investors" section of Halozyme's corporate website at www.halozyme.com. About Halozyme Halozyme is a bioph

Updates Preliminary Unaudited 2025 Estimates:- Total Revenue of $1,385 - $1,400 million, YoY Growth of 36% to 38%1- Royalty Revenue of $865 - $870 million, YoY Growth of 51% to 52%1 Raises 2026 Financial Guidance Ranges: - Increases Total Revenue to $1,710 - $1,810 million, YoY Growth of 23% to 30%2 - Increases Royalty Revenue to $1,130 - $1,170 million, YoY Growth of 30% to 35%2 - Increases Adjusted EBITDA to $1,125 - $1,205 million3,4- Increases non-GAAP Diluted EPS to $7.75 - $8.253,4 Expands Drug Delivery Opportunity with Acquisition of Surf Bio and its Hyperconcentration Technology Conference Call Scheduled Today at 5:30am PT/8:30am ET SAN DIEGO, Jan. 28, 2026 /PRNewswire/ -- Halozyme T

SAN DIEGO, Jan. 20, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced it will host an Investor Conference Call on Wednesday, January 28, 2026, at 5:30 am PT / 8:30 am ET. On the call, Dr. Helen Torley, President and Chief Executive Officer, and Nicole LaBrosse, Chief Financial Officer, will provide preliminary unaudited full year 2025 revenue results, updated 2026-2028 financial guidance and a business update. Pre-registration of the live call can be accessed via link here: https://registrations.events/direct/Q4I1205969. The call will also be webcast live through the "Investors" section of Halozyme's corporate website and a recording will be made ava

Royalty Revenue Increased 52% YOY to Record $236 million and Total Revenue Increased 22% YOY to Record $354 million Net Income Increased 28% YOY to $175 million; Adjusted EBITDA Increased 35% YOY to $248 million; GAAP Diluted EPS Increased 36% YOY to $1.43; Non-GAAP Diluted EPS Increased 35% YOY to $1.721 Raising 2025 Financial Guidance Ranges for Total Revenue to $1,300 - $1,375 million, Representing YOY Growth of 28% - 35%, Adjusted EBITDA to $885 - $935 million, Representing YOY Growth of 40% - 48% and Non-GAAP Diluted EPS to $6.10 - $6.50, Representing YOY Growth of 44% - 54%1 Announces Chief Financial Officer Transition Plan SAN DIEGO, Nov. 3, 2025 /PRNewswire/ -- Halozyme Therapeutics

SAN DIEGO, Oct. 21, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced it will release its third quarter 2025 financial and operating results on Monday, November 3, 2025, following the close of trading. Halozyme will host a conference call on Monday, November 3, 2025 at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. The conference call may be accessed live with pre-registration via this link https://registrations.events/direct/Q4I78137280. A live webcast and replay of the conference call will also be available through the "Investors" section of Halozyme's corporate website at www.halozyme.com. About Halozyme Halozyme is a biopharmaceutical company

Royalty revenue contribution expected to begin as early as 2030 Initial partner targets include derisked MoAs that are approved blockbusters today Highly scalable licensing model and long duration IP into 2040s; potential for individual product IP extension through proprietary reformulation Two of Elektrofi's partners projected to begin Hypercon™ formulated product clinical development by year end 2026, or earlier Halozyme to host conference call and webcast today at 5:30am PT/ 8:30am ET SAN DIEGO, Oct. 1, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced it has entered into a definitive agreement to acquire Elektrofi, Inc. ("Elektrofi"), a biopharm

Total Revenue Increased 41% YOY to $326 million and Royalty Revenue Increased 65% YOY to $206 million Net Income Increased 77% YOY to $165 million; Adjusted EBITDA Increased 65% YOY to $226 million; GAAP Diluted EPS Increased 85% YOY to $1.33; Non-GAAP Diluted EPS Increased 69% YOY to $1.541 Raising 2025 Financial Guidance Ranges for Total Revenue to $1,275 - $1,355 million, Representing YOY Growth of 26% - 33%, Adjusted EBITDA to $865 - $915 million, Representing YOY Growth of 37% - 45% and Non-GAAP Diluted EPS to $6.00 - $6.40, Representing YOY Growth of 42% - 51%1 Announcing Third $250 million Share Repurchase Tranche Under $750 million Authorized Plan  SAN DIEGO, Aug. 5, 2025 /PRNewswir

SAN DIEGO, July 22, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced it will release its second quarter 2025 financial and operating results on Tuesday, August 5, 2025, following the close of trading. Halozyme will host a conference call on Tuesday, August 5, 2025 at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. The conference call may be accessed live with pre-registration via this link https://registrations.events/direct/Q4I78137779. A live webcast and replay of the conference call will also be available through the "Investors" section of Halozyme's corporate website at www.halozyme.com. About Halozyme Halozyme is a biopharmaceutical company a

SAN DIEGO, June 30, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) (Halozyme) today announced that it has been added to the U.S. large-cap Russell 1000® Index, effective after market close on June 27th, as part of the 2025 FTSE Russell indexes annual reconstitution. The Russell 1000® Index includes approximately 1,000 of the largest U.S. securities based on market capitalization and is widely used by investors as a benchmark for the performance of large-cap stocks. "Joining the Russell 1000 Index is an important milestone that reflects our leadership in rapid large-volume subcutaneous drug delivery and our track record of durable top-and-bottom line growth," said Dr. Helen To

Announcing New $250M Share Repurchase  Total Revenue Increased 35% YOY to $265 million and Royalty Revenue Increased 39% YOY to $168 million Net Income Increased 54% YOY to $118 million; Adjusted EBITDA Increased 40% YOY to $162 million; GAAP Diluted EPS Increased 55% YOY to $0.93; non-GAAP Diluted EPS Increased 41% YOY to $1.111 Raising 2025 Financial Guidance Ranges for Total Revenue to $1,200 - $1,280 million, Representing YOY Growth of 18% - 26%, Adjusted EBITDA to $790 - $840 million, Representing YOY Growth of 25% - 33% and non-GAAP Diluted EPS to $5.30 - $5.70, Representing YOY Growth of 25% - 35%1 SAN DIEGO, May 6, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Hal

SAN DIEGO, April 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced it will release its first quarter 2025 financial and operating results on Tuesday, May 6, 2025, following the close of trading. Halozyme will host a conference call on Tuesday, May 6, 2025 at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. The conference call may be accessed live with pre-registration via this link: https://registrations.events/direct/Q4I7813723. A live webcast and replay of the conference call will also be available through the "Investors" section of Halozyme's corporate website at www.halozyme.com. About Halozyme Halozyme is a biopharmaceutical company advanci

Fourth Quarter Total Revenue Increased 30% YOY to $298 million and Royalty Revenue Increased 40% YOY to $170 million Fourth Quarter Net Income Increased 60% YOY to $137 million; Adjusted EBITDA Increased 61% YOY to $196 million; GAAP EPS Increased 63% YOY to $1.06; non-GAAP EPS Increased 54% YOY to $1.261 Record Full Year 2024 Total Revenue Increased 22% YOY to $1,015 million and Record Royalty Revenue Exceeded Guidance Increasing 27% YOY to $571 million Full Year 2024 Net Income Increased 58% YOY to $444 million; GAAP EPS Increased 63% YOY to $3.43; Adjusted EBITDA Increased 48% YOY to $632 million and non-GAAP EPS Increased 53% YOY to $4.231, Both Exceeding Guidance  Reiterating 2025 Finan

SAN DIEGO, Feb. 4, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced it will release its fourth quarter and full year 2024 financial and operating results on Tuesday, February 18, 2025, following the close of trading. Halozyme will host a conference call on Tuesday, February 18, 2025 at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. The conference call may be accessed live with pre-registration via this link: https://registrations.events/direct/Q4I7813760. A live webcast and replay of the conference call will also be available through the "Investors" section of Halozyme's corporate website at www.halozyme.com. About Halozyme Halozyme is a biopharm

Reports Preliminary 2024 Unaudited Estimated Ranges Consistent with Previous Financial Guidance  Raises 2025 Financial Guidance Ranges for Total Revenue to $1,150 - $1,225 million, Representing YoY Growth of 16% - 23%, Adjusted EBITDA of $755 - $805 million, Representing YoY Growth of 24% - 32%, and non-GAAP Diluted EPS of $4.95 - $5.35, Representing YoY Growth of 21% - 30%1,2 Announces New $250 million Accelerated Share Repurchase Conference Call Scheduled Today at 5:30am PT/8:30am ET SAN DIEGO, Jan. 8, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today provided a financial update, reiterating full year 2024 financial guidance and raising full

SAN DIEGO, Jan. 6, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced it will host an Investor Conference Call on Wednesday, January 8, 2025, at 5:30 a.m. PT / 8:30 a.m. ET. On the call, Dr. Helen Torley, President and Chief Executive Officer, and Nicole LaBrosse, Chief Financial Officer, will provide preliminary unaudited full year 2024 results and updated 2025 and multi-year financial guidance. Pre-registration of the live call can be accessed via link here: https://registrations.events/direct/Q4I871904593. The call will also be webcast live through the "Investors" section of Halozyme's corporate website and a recording will be made available follow

Total Revenue Increased 34% YOY to $290 million and Royalty Revenue Increased 36% YOY to $155 million Net Income Increased 67% YOY to $137 million and Adjusted EBITDA Increased 60% YOY to $184 million GAAP Diluted EPS Increased 72% YOY to $1.05 and Non-GAAP Diluted EPS Increased 69% YOY to $1.271 Raised 2024 Financial Guidance Ranges for Total Revenue of $970-$1,020 million, Representing YOY Growth of 17%-23%, Adjusted EBITDA of $595-$625 million, Representing YOY Growth of 40%-47%, and Non-GAAP Diluted EPS of $4.00-$4.20, Representing YOY Growth of 44%-52% SAN DIEGO, Oct. 31, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today reported its fina

Company Projects No Impact on U.S. or European Royalty Revenues from DARZALEX FASPRO® and SC through 2032 Reiterates 2024 Royalty Revenue Guidance of $520-555 million and Expectations to Generate >$1 billion in 2027 Conference Call Scheduled Today, Thursday, October 24 at 5:30am PT/8:30am ET SAN DIEGO, Oct. 24, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) today provided an update following a decision by the Opposition Division of the European Patent Office ("EPO") to revoke one of the Janssen Biotech, Inc. (Janssen) co-formulation patents for DARZALEX® (daratumumab) SC (Patent EP 3827845). "We remain confident in our strong royalty revenue projections with 8 approved partne

SAN DIEGO, Oct. 23, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced it will release its third quarter 2024 financial and operating results on Thursday, October 31, 2024, following the close of trading. Halozyme will host a conference call on Thursday, October 31, 2024 at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. The conference call may be accessed live with pre-registration via this link: https://registrations.events/direct/Q4I7813747. A live webcast and replay of the conference call will also be available through the "Investors" section of Halozyme's corporate website at www.halozyme.com. About Halozyme Halozyme is a biopharmaceutical comp

Total Revenue of $231 million; Net Income of $93 million; Adjusted EBITDA of $137 million; GAAP Diluted EPS of $0.72 and Non-GAAP Diluted EPS of $0.911 Royalty Revenue Increased 12% YOY to $125 million Partner Approvals for Ocrevus® SC in Europe and the UK and VYVGART® Hytrulo for CIDP in the U.S. Maintain Recently Increased 2024 Financial Guidance: Total Revenue of $935 - $1,015 million, Representing YOY Growth of 13% - 22%, Adjusted EBITDA of $555 - $615 million, Representing YOY Growth of 30% - 44% and Non-GAAP Diluted EPS of $3.65 - $4.05, Representing YOY Growth of 32% - 46% SAN DIEGO, Aug. 6, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") t

SAN DIEGO, July 23, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced it will release its second quarter 2024 financial and operating results on Tuesday, August 6, 2024, following the close of trading. Halozyme will host a conference call on Tuesday, August 6, 2024 at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. The conference call may be accessed live with pre-registration via this link: https://registrations.events/direct/Q4I8719057. A live webcast and replay of the conference call will also be available through the "Investors" section of Halozyme's corporate website at www.halozyme.com. About Halozyme Halozyme is a biopharmaceutical company a

Company Granted New European Patent for ENHANZE® Drug Delivery Platform SAN DIEGO, June 6, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced that the Company is raising its full year 2024 financial guidance and updating its 5-year financial outlook based on the grant of European Patent No. 4269578, covering the ENHANZE® rHuPH20 product obtained from Halozyme's ENHANZE® manufacturing methods that the Company provides to its current and future licensees. The new patent is licensed under all of Halozyme's ENHANZE® licenses. It will be validated in 37 European countries and expires on March 6, 2029. "We are pleased to be able to raise our full year 2024

Conference Call Scheduled for Thursday, June 6 at 5:30am PT/8:30am ET SAN DIEGO, June 5, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced the grant of European Patent No. 4269578, covering the ENHANZE® rHuPH20 product obtained from Halozyme's ENHANZE® manufacturing methods that the Company provides to its current and future licensees. The new patent is licensed under all of Halozyme's ENHANZE® licenses. It will be validated in 37 European countries and expires on March 6, 2029. "This new European patent for ENHANZE further strengthens our robust patent estate and extends the durability of our portfolio," said Dr. Helen Torley, president and chief ex

Revenue Increased 21% YOY to $196 million; Net Income of $77 million; Adjusted EBITDA of $116 million; GAAP Diluted EPS of $0.60 and Non-GAAP Diluted EPS of $0.791 Royalty Revenue Increased 21% YOY to $121 million Reiterating 2024 Financial Guidance: Total Revenue of $915 - $985 million, Representing YOY Growth of 10% - 19%, Adjusted EBITDA of $535 - $585 million, Representing YOY Growth of 26% - 37% and Non-GAAP Diluted EPS of $3.55 - $3.90, Representing YOY Growth of 28% - 41% Announced New $750 million Share Repurchase Program SAN DIEGO, May 7, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today reported its financial and operating results fo

SAN DIEGO, April 23, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced it will release its first quarter 2024 financial and operating results on Tuesday, May 7, 2024, following the close of trading. Halozyme will host a conference call on Tuesday, May 7, 2024 at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. The conference call may be accessed live with pre-registration via this link: https://registrations.events/direct/Q4I871907. A live webcast and replay of the conference call will also be available through the "Investors" section of Halozyme's corporate website at www.halozyme.com. About Halozyme Halozyme is a biopharmaceutical company advancin

Reiterating 2024 Financial Guidance: Total Revenue of $915-985 Million, Representing YOY Growth of 10-19%, Adjusted EBITDA of $535-585 Million, Representing YOY Growth of 26- 37% and Non-GAAP Diluted EPS of $3.55-3.90, Representing YOY Growth of 28-41% Fourth Quarter Revenue Increased 27% YOY to $230 million; GAAP Diluted EPS of $0.65 and Non-GAAP Diluted EPS of $0.821 Full Year 2023 Revenue Increased 26% YOY to $829 million; GAAP Diluted EPS of $2.10 and Non-GAAP Diluted EPS of $2.771 Announcing New $750 million Share Repurchase Program SAN DIEGO, Feb. 20, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today reported its financial and operating

SAN DIEGO, Feb. 8, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced it will release its fourth quarter and full year 2023 financial and operating results on Tuesday, February 20, 2024, following the close of trading. Halozyme will host a conference call on Tuesday, February 20, 2024 at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. The conference call may be accessed live with pre-registration via this link: https://registrations.events/direct/Q4I871904. A live webcast and replay of the conference call will also be available through the "Investors" section of Halozyme's corporate website at www.halozyme.com. About Halozyme Halozyme is a biopharma

SAN DIEGO, Jan. 12, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced that it will host an Investor Business Forum and Long-Term Outlook Call on Wednesday, January 17, 2024 at 5:30 a.m. PT / 8:30 a.m. ET. On the call, Dr. Helen Torley, President and Chief Executive Officer will be joined by Mark Snyder, Chief Legal Officer and Nicole LaBrosse, Chief Financial Officer to present detailed guidance around the patent dynamics that are expected to drive revenue durability of Halozyme's ENHANZE® drug delivery technology.  The company will also provide 2024 financial guidance as well as long term financial outlook. A webcast of the live call can be accessed

Revenue Increased 45% YOY to $221.0 million; GAAP Diluted EPS of $0.56 and Non-GAAP Diluted EPS of $0.741  Royalty Revenue Increased 31% YOY to Record $111.7 million Raised 2023 Non-GAAP Diluted EPS Guidance to $2.65-$2.75 Updated Revenue Guidance to $825-$845 million, Representing 25-28% YOY Growth, and EBITDA Guidance to $420-$440 million, Representing >30% YOY Growth1     SAN DIEGO, Aug. 8, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today reported its financial and operating results for the second quarter ended June 30, 2023 and provided an update on its recent corporate activities and outlook. "Our strong second quarter results with reco

SAN DIEGO, July 25, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced it will release its second quarter 2023 financial and operating results on Tuesday, August 8, 2023, following the close of trading. Halozyme will host a conference call on Tuesday, August 8, 2023 at 4:30 p.m. ET/1:30 p.m. PT to discuss the results. The conference call may be accessed live with pre-registration via this link: https://events.q4inc.com/attendee/874394866. A live webcast and replay of the conference call will also be available through the "Investors" section of Halozyme's corporate website at www.halozyme.com. About Halozyme Halozyme is a biopharmaceutical company brin

Revenue Increased 38% YOY to $162.1 million; GAAP Diluted Earnings per Share of $0.29 and Non-GAAP Diluted Earnings per Share of $0.471 Royalty Revenue Increased 43% YOY to $99.6 million Reiterating 2023 Revenue Guidance of $815-$845 million, Representing 23-28% YOY Growth; EBITDA of $415-$440 million, Representing >30% YOY Growth1     SAN DIEGO, May 9, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today reported its financial and operating results for the first quarter ended March 31, 2023 and provided an update on its recent corporate activities and outlook. "We executed to our plan in the first quarter with total year-over-year revenue growth of 38% to $162

SAN DIEGO, April 25, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced it will release its first quarter 2023 financial and operating results on Tuesday, May 9, 2023, following the close of trading. Halozyme will host a conference call on Tuesday, May 9, 2023 at 4:30 p.m. ET/1:30 p.m. PT to discuss the results. The conference call may be accessed live with pre-registration via this link: https://conferencingportals.com/event/QfiVLXsr A live webcast and replay of the conference call will also be available through the "Investors" section of Halozyme's corporate website at www.halozyme.com. About Halozyme Halozyme is a biopharmaceutical company bringing

Fourth Quarter Revenue Increased 78% YOY to $181 million; GAAP Diluted Earnings per Share of $0.42 and Non-GAAP Diluted Earnings per Share of $0.481 Full Year 2022 Revenue Increased 49% YOY to $660.1 million; GAAP Diluted Earnings per Share of $1.44 and Non-GAAP Diluted Earnings per Share of $2.211 Record Fourth Quarter Royalty Revenue Increased 69% YOY to $106.0 million; Record Full Year Royalty Revenue Increased 77% YOY to $360.5 million 2023 Revenue Guidance of $815 million to $845 million, Representing 23%-28% YOY Growth; EBITDA of $415 million to $440 million, Representing >30% YOY Growth 1     SAN DIEGO, Feb. 21, 2023  /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Haloz

SAN DIEGO, Feb. 7, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced it will release its fourth quarter and full year 2022 financial and operating results on Tuesday, February 21, 2023, following the close of trading. Halozyme will host a conference call on Tuesday, February 21, 2023 at 4:30 p.m. ET/1:30 p.m. PT to discuss the results. The conference call may be accessed live with pre-registration via this link: https://conferencingportals.com/event/QfiVLXsr. A live webcast and replay of the conference call will also be available through the "Investors" section of Halozyme's corporate website at www.halozyme.com. About Halozyme Halozyme is a biopharm

Third Quarter Revenue Increased 80% YOY to $209 Million, with GAAP Diluted Earnings per Share of $0.44 and Non-GAAP Diluted Earnings per Share of $0.741 Record Third Quarter Royalty Revenue Increased 70% YOY to $99.6 Million Reiterating 2022 Revenue Guidance of $655 Million to $685 Million, Representing 48%-55% Growth over Reported 2021 Revenue      SAN DIEGO, Nov. 8, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today reported its financial and operating results for the third quarter ended September 30, 2022 and provided an update on its recent corporate activities and outlook. "Our third quarter accomplishments are reflective of the expanded opportunities an

SAN DIEGO, Oct. 25, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced it will release its third quarter 2022 financial and operating results on Tuesday, November 8, 2022, following the close of trading. Halozyme will host a conference call on Tuesday, November 8, 2022 at 4:30 p.m. ET to discuss the results. The conference call may be accessed live with pre-registration via this link: https://conferencingportals.com/event/QfiVLXsr. A live webcast and replay of the conference call will also be available online on the investor relations section of the Halozyme Therapeutics corporate website at www.halozyme.com. About Halozyme Therapeutics, Inc.Halozyme

Closed Antares Pharma Acquisition, Accelerating High Growth Drug Delivery Leadership and Projected to be Accretive to Revenue for Full Year 2022 Second Quarter Revenue Increased 12% YOY to $152.4 million, with GAAP Diluted Earnings per Share of $0.16 and Non-GAAP Diluted Earnings per Share of $0.53 Record Second Quarter Royalty Revenue Increased 86% YOY to $85.3 million Raising 2022 Revenue Guidance to $655 Million to $685 Million, up from $530 Million to $560 Million, Representing 48%-55% Growth over Reported 2021 Revenue      SAN DIEGO, Aug. 9, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today reported its financial and operating results for the second qua

SAN DIEGO, July 26, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced it will release its second quarter 2022 financial and operating results on Tuesday, August 9, 2022, following the close of trading. Halozyme will host a conference call on Tuesday, August 9, 2022 at 4:30 p.m. ET to discuss the results. The dial-in numbers are (888) 330-2408 for domestic callers and (240) 789-2703 for international callers. The conference ID number is 89853. A live webcast and replay of the conference call will be available online on the investor relations section of the Halozyme Therapeutics corporate website at www.halozyme.com. About HalozymeHalozyme is a biophar

First Quarter Revenue of $117.3 million, Representing a 32% YOY Increase, with GAAP Diluted Earnings per Share of $0.43 and Non-GAAP Diluted Earnings per Share of $0.47 Record Quarterly Royalties in the First Quarter of $69.6 million, Representing 89% Growth over First Quarter 2021 Reiterate 2022 Revenue Guidance of $530 Million to $560 Million, Representing 20-26% Growth over Reported 2021 Revenue Reiterate 2022 GAAP Operating Income Guidance of $350 million to $380 million, Representing 27%-38% Growth over 2021 GAAP Operating Income SAN DIEGO, May 10, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today reported financial results for the first quarter ended Ma

SAN DIEGO, May 3, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) will webcast its Quarterly Update Conference Call for the first quarter 2022 on May 10 at 4:30 p.m. ET / 1:30 p.m. PT. Dr. Helen Torley, president, and chief executive officer, will lead the call. On the same date, Halozyme will release financial results for the first quarter ended March 31, 2022, following the close of trading. To register for this conference call, please use this link: https://events.q4inc.com/attendee/321325561. After registering, you will receive an email confirmation that inc

Transaction Expected to be Immediately Accretive to Revenue and Non-GAAP Earnings in 2022 with Multiple Drivers to Accelerate Financial Growth Through 2027 and Beyond Augments Drug Delivery Business with Best-in-Class Auto Injector Platform with Broad Licensing Potential Diversifies Revenue Mix with Addition of Growing Testosterone Replacement Therapy Product Revenues to Anchor Commercial Opportunity with Key Targeted Audiences Creates a Leading Drug Delivery Business with Broadly Licensable Opportunities across ENHANZE and Antares Auto Injector Platforms Halozyme to Host Conference Call and Webcast Today at 8:00 a.m. ET/5:00 a.m. PT SAN DIEGO and EWING, N.J., April 13, 2022 /PRNewswire/

SAN DIEGO, Feb. 22, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) today reported financial results for the fourth quarter and full year ended December 31, 2021, and provided an update on its recent corporate activities and outlook. "Our performance in the fourth quarter closed out a year of strong performance across our business highlighted by record full year revenue from royalties, growing 130% from last year driven by the continued adoption of our wave 2 partner products subcutaneous DARZALEX® and Phesgo® (pertuzumab, trastuzumab, and hyaluronidase-zzxf)," said Dr. Helen Torley, president and chief executive officer. "In 2022, we look forward to building on 2021 momentum

SAN DIEGO, Feb. 9, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) will webcast its Quarterly Update Conference Call for the fourth quarter 2021 on Tuesday, February 22 at 4:30 p.m. ET / 1:30 p.m. PT. Dr. Helen Torley, president and chief executive officer, will lead the call. On the same date, Halozyme will release financial results for the fourth quarter and year ended December 31, 2021, following the close of trading. To register for this conference call, please use this link: https://conferencingportals.com/event/iCFaInWc. After registering, you will receive an email confirmation that includes dial in details and unique conference call codes for entry. Registration is open

SAN DIEGO, Nov. 2, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) today reported financial results for the third quarter ended September 30, 2021 and provided an update on its recent corporate activities and outlook. "Our strong 2021 performance continued in the third quarter fueled by 145% growth over the prior year period in revenue from royalties. We continue to project that full year royalty revenue in 2021 will be more than double 2020 royalty revenue.  Our topline growth in turn resulted in strong profitability for the quarter," said Dr. Helen Torley, president and chief executive officer. "We look forward to additional study starts before year-end as our partners conti

SAN DIEGO, Oct. 19, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) will webcast its Quarterly Update Conference Call for the third quarter 2021 on November 2 at 4:30 p.m. ET / 1:30 p.m. PT. Dr. Helen Torley, president and chief executive officer, will lead the call. On the same date, Halozyme will release financial results for the third quarter ended September 30, 2021, following the close of trading. To register for this conference call, please use this link:https://event.on24.com/wcc/r/3409153/C35CE25D8E989A50B9CD4A9747276C3E. After registering, you will receive an email confirmation that includes dial in details and unique conference call codes for entry. Registration is o

SAN DIEGO, Aug. 9, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) today reported financial results for the second quarter ended June 30, 2021 and provided an update on its recent corporate activities and outlook. "Our excellent start to 2021 continued in the second quarter with strong quarterly growth resulting in record quarterly revenues from royalties and the signing of our eleventh collaboration and license agreement," said Dr. Helen Torley, president and chief executive officer. "Our recently announced collaboration with ViiV Healthcare demonstrates the potential for our ENHANZE® technology to meet evolving patients' needs by creating long-acting drugs that facilitate ra

SAN DIEGO, July 27, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) will webcast its Quarterly Update Conference Call for the second quarter 2021 on Monday, August 9 at 4:30 p.m. ET / 1:30 p.m. PT. Dr. Helen Torley, president and chief executive officer, will lead the call. On the same date, Halozyme will release financial results for the second quarter ended June 30, 2021 following the close of trading. To register for this conference call, please use this link: http://www.directeventreg.com/registration/event/5694076. After registering, you will receive an email confirmation that includes dial in details and unique conference call codes for entry. Registration is open throug